Women's menstrual cycles temporarily became a little longer after receiving a flu shot, regardless of whether they also ...

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Wall Street analysts expect Organon (OGN) to post quarterly earnings of $0.92 per share in its upcoming report, which indicates a year-over-year decline of 24.6%. Revenues are expected to be $1.54 ...

And not just two or three times more—exponentially more. One reason for this is medical health care has thousands more quantifiable measures of illness that can be billed than mental health care does.

Organon has acquired regulatory and commercial rights in the United States from Biogen for Tofidence, a biosimilar to Actemra for intravenous infusion. Tofidence, the first approved tocilizumab ...

Is now the time to buy Super Micro? Access our full analysis report here, it’s free. Branded Pharmaceuticals company Organon (NYSE:OGN) jumped 7%. Is now the time to buy Organon? Access our full ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), with a price target of $15.00. The company’s shares closed last ...

Organon & Co. has a 1-year low of $12.15 and a 1-year high of $23.10. The company has a market cap of $3.23 billion, a PE ratio of 3.76, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73.

Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama Women’s health drugmaker Organon is also initiating New Jersey layoffs, to the tune of 93 staffers in Jersey ...